Panretin (alitretinoin)
- Region
- 🇪🇺 EU
- Active substance
- alitretinoin
- Company
- Eisai GmbH
- Status
- Withdrawn
- Therapeutic area
- Sarcoma, Kaposi
- EU approval
- Wed 11 Oct 2000
- Application
- EMEA/H/C/000279
- ATC
- L01XX22
- Official record
- www.ema.europa.eu
Indication
Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when: lesions are not ulcerated or lymphoedematous, and; treatment of visceral KS is not required, and; lesions are not responding to systemic antiretroviral therapy, and; radiotherapy or chemotherapy are not appropriate.
Regulatory milestones
No milestones recorded in the last year.
Follow Panretin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.